International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn:
“What did ASCO 2025 deliver for lung cancer research?
In this episode of Lung Cancer Considered, Drs. Narjust Florez, Stephen Liu, Charu Aggarwal, and Patrick Forde review key lung cancer data from ASCO25 – including the CheckMate 816, HERTHENA-Lung02, NEOADAURA, REZILIENT1, SWOG Pragmatica, IMforte, and SOHO-01 trials.
Get expert analysis on what these results mean for clinical practice and research moving forward! Listen now.”
More posts featuring IASLC.